News
U.S. kidney transplants grow in number and success
August 24, 2021
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
![1]()
News
SGLT2 inhibitor use rising in patients with DKD
August 23, 2021
Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.
News
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
News
Patients with diabetes more likely to be hospitalized, especially with foot infection
August 9, 2021
Participants with diabetes faced a 67% increased risk of infection-related hospitalization, compared with those without diabetes.
![1]()
News
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.
![1]()
News
Unmanaged diabetes, high blood glucose tied to COVID-19 severity
June 26, 2021
Findings suggest in part that hospitalized COVID-19 patients need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes or A1c value.
![1]()
News
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
June 23, 2021
The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.
News
More obese, diabetic, chronically ill kids hospitalized with COVID-19
June 16, 2021
Children with diabetes, obesity, and cardiac and circulatory congenital anomalies were more likely to be hospitalized with COVID-19 and to be severely ill while hospitalized, a new study finds.
![1]()
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
May 24, 2021
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.
![1]()
News
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
May 18, 2021
A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone significantly cut new-onset AFib.
